KIT and ovarian carcinoma: It has been repeatedly shown that CD117 (a product of the c-KIT gene) is expressed in many aggressive cancers (including ovarian cancers) as well as in recurrent and resistant tumors and predicts poor survival of patients (Chau et al., 2013; Conic et al., 2015; Stemberger-Papić et al., 2015; Yang et al., 2017; Foster et al., 2018; Fang et al., 2020).